267 related articles for article (PubMed ID: 8794610)
1. Maximal androgen blockade (MAB) for the treatment of prostate cancer.
Kirby RS
Br J Clin Pract; 1996; 50(5):287. PubMed ID: 8794610
[No Abstract] [Full Text] [Related]
2. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
3. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
4. [Total androgen blockade].
Namiki M; Mizokami A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
[No Abstract] [Full Text] [Related]
5. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
[No Abstract] [Full Text] [Related]
6. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Collette L; Studer UE; Schröder FH; Denis LJ; Sylvester RJ
Prostate; 2001 Jun; 48(1):29-39. PubMed ID: 11391684
[TBL] [Abstract][Full Text] [Related]
7. [Antiandrogen in prostate cancer].
Maeda O; Usami M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
[No Abstract] [Full Text] [Related]
8. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
9. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
10. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness and positioning of MAB therapy for prostate cancer].
Akaza H; Chodak GW; Hirao Y
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
[TBL] [Abstract][Full Text] [Related]
12. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
13. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
14. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
15. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
17. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
18. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
[TBL] [Abstract][Full Text] [Related]
19. Editorial comment.
Shepard DR
Urology; 2010 May; 75(5):1137. PubMed ID: 20451735
[No Abstract] [Full Text] [Related]
20. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Yoshida T
Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
[No Abstract] [Full Text] [Related]
[Next] [New Search]